Abstract: SA-PO0384
Inside CKD-HTN: The Effect of Hypertension Control Across KDIGO Risk Categories on CKD Burden
Session Information
- CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Chertow, Glenn M., Stanford University School of Medicine, Stanford, California, United States
- Tangri, Navdeep, University of Manitoba, Winnipeg, Manitoba, Canada
- Chadban, Steven J., Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Garcia Sanchez, Juan Jose, AstraZeneca Global Modelling Group, Barcelona, Spain
- Retat, Lise, AstraZeneca Global Modelling Group, Barcelona, Spain
- Danelich, Ilya, AstraZeneca Global Modelling Group, Barcelona, Spain
- Agiro, Abiy, AstraZeneca US Medical Affairs, Wilmington, Delaware, United States
- Coker, Timothy, HealthLumen Ltd, London, England, United Kingdom
- Card-Gowers, Joshua, HealthLumen Ltd, London, England, United Kingdom
- Ocazionez-Cardozo, Francisco Jesus, HealthLumen Ltd, London, England, United Kingdom
- Llanes-Kidder, Camila, HealthLumen Ltd, London, England, United Kingdom
Background
Up to 90% of patients with chronic kidney disease (CKD) have hypertension (HTN), and 60–80% may not achieve systolic blood pressure (SBP) goals. Population-level HTN control across Kidney Disease: Improving Global Outcomes (KDIGO) risk groups is poorly described. We estimated HTN control and cardiovascular disease (CVD) prevalence across KDIGO risk groups.
Methods
We analysed NHANES data (2015–2023), stratified by KDIGO risk, sex, and age (<65 vs. ≥65). HTN status was defined by prior diagnosis/treatment and SBP, categorised as no HTN, controlled, or uncontrolled. CVD prevalence (heart failure, myocardial infarction, stroke) was assessed. Control was defined as SBP <120 mmHg in CKD and <130 mmHg in non-CKD.
Results
HTN prevalence was higher in very-high versus low-risk (82.6% vs. 25.9%); uncontrolled HTN was higher in very-high versus low-risk (69.5% vs. 10.9%). In persons <65 years, uncontrolled HTN was higher in very-high versus low-risk (70.3% vs. 7.9%); corresponding values in persons ≥65 years were 69.2% vs. 27.5%. In adults ≥65 years, HTN control was lower in very-high versus low-risk (13.9% vs. 22.9%).
CVD prevalence was 8-fold higher in the very-high group relative to the low-risk (39.8% vs. 5.0%). HTN prevalence was higher in low-risk persons with versus without CVD (65.9% vs. 23.8%); 30.5% were uncontrolled.
Conclusion
HTN and CVD burden were higher with greater KDIGO risk. Uncontrolled HTN was ~70% across very-high-risk subgroups. HTN burden gradients were steeper in younger persons, while control was lower in older persons. These findings highlight opportunities to improve outcomes in CKD through earlier HTN management.
HTN prevalence and age specific control by KDIGO risk.
CVD prevalence and HTN control by CVD status.
Funding
- Commercial Support – AstraZeneca